Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02080390 · ClinicalTrials.gov registry record
Strain Imaging in Breast Cancer Patients Receiving Trastuzumab
A clinical trial of HER2-positive Breast Cancer, sponsored by University of Florida.
- Completed
- Registry status
- 25
- Enrollment target
- 1
- Study location
NCT02080390: Completed study of HER2-positive Breast Cancer, sponsored by University of Florida.
NCT02080390 is a study of HER2-positive Breast Cancer that has completed, run by University of Florida. The registered enrollment target is 25 participants, below the 235-participant average among 58 other HER2-positive Breast Cancer trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02080390, a study of HER2-positive Breast Cancer, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to evaluate the effects of the chemotherapeutic drug, Trastuzumab (Herceptin) on the heart. Trastuzumab (Herceptin) is used to treat specific types of breast cancer and is known to cause weakening of the heart. Unfortunately, little is know as to why this this happens. The investigators want to identify any factors that may lead to the early detection, treatment and prevention of the cardiotoxicity (heart problem) associated with this drug.
Primary Outcome
Each transthoracic echocardiogram obtained during the patient's treatment will be assessed for longitudinal strain.
Conditions Studied
Interventions
- PROCEDURE Transthoracic echocardiogram (ultrasound)
Study Locations (1)
Florida
- Univerisity of Florida - Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2014-09 |
| Est. Completion | 2019-02-14 |
What the finished NCT02080390 record still lists
NCT02080390 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 235-participant average among 58 other HER2-positive Breast Cancer trials with a reported enrollment target (89% lower).
The record links to 1 condition, with HER2-positive Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Transthoracic echocardiogram (ultrasound) is the first listed.
NCT02080390 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT02080390 about?
NCT02080390 is a clinical study titled "Strain Imaging in Breast Cancer Patients Receiving Trastuzumab". The purpose of this research study is to evaluate the effects of the chemotherapeutic drug, Trastuzumab (Herceptin) on the heart. Trastuzumab (Herceptin) is used to treat specific types of breast cancer and is known to cause weakening of the heart. Unfortunately, little is know as to why this this h...
What is the current status of trial NCT02080390?
This trial is currently completed. The enrollment target is 25 participants. The study started on 2014-09. Estimated completion is 2019-02-14.
What conditions does trial NCT02080390 study?
This clinical trial studies the following conditions: HER2-positive Breast Cancer.
What interventions are being tested in trial NCT02080390?
The interventions under investigation include: Transthoracic echocardiogram (ultrasound) (PROCEDURE).
Who is sponsoring clinical trial NCT02080390?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02080390 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HER2-positive Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02080390's enrollment target sits among peer trials
25 47th of 58 higher than 11 of 58 other HER2-positive Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HER2-positive Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
TRUDI: TDXD+Durva in HER2+/Low IBC
RECRUITING · Phase 2
-
HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission
RECRUITING · Phase 2
-
A Phase 1/1b Study of IAM1363 in HER2 Cancers
RECRUITING · Phase 1
-
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
RECRUITING · Phase 2
-
A Study of Surgery and Radiotherapy in People With Breast Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia